News

The investigators concluded that these findings have implications which suggest that transferring patients for late-window thrombectomy is associated with substantial clinical benefits and should be strongly encouraged.

The director of the mitochondrial research program at Akron Children’s Hospital spoke about how to best manage a condition such as PMM, where there are no FDA-approved therapies.

The study provided Class I evidence that the ALSDI can help the confirmation and diagnosis of ALS and its mimicking conditions at the earliest stages of the disease, when therapeutic efforts are most efficacious.

The neurosurgeon at The Ohio State University Wexner Medical Center and lead investigator of the first-in-world trial spoke about the study’s goals and the potential of the treatment.

The microdystrophin gene transfer therapy from Solid Biosciences has shown protein expression in the first 3 patients dosed. As a result, the company is expediting the planned dose-escalating activities.

Findings from a cross-sectional exploration have suggested that biological differences between men and women may explain the higher risk for Alzheimer faced by women.

The executive vice president and chief medical officer of Zogenix spoke about what sets the fenfluramine agent apart and what clinicians need to know after its NDA submission.

The professor of pediatrics at Northeast Ohio Medical University and the director of the NeuroDevelopmental Science Center at Akron Children’s Hospital provided insight into the therapeutic landscape of PMM.

Guidelines from the American Academy of Neurology now cover the use of third-generation antiepileptic drugs for patients with new-onset focal or generalized epilepsy.

The stroke specialist at the Cerebrovascular Center at Cleveland Clinic detailed how patients who were rehabilitated earlier were shown to have better outcomes and a shorter stay in the intensive care unit in this study.

The initial phase 2 studies of cenobamate evaluated close to 1000 individuals, with efficacy demonstrated to the point that the FDA did not require additional efficacy studies.

The NDA for Zogenix's fenfluramine therapy is supported by data from 2 phase 3 trials in Dravet syndrome, as well as an interim analysis from the company’s ongoing open-label extension study, which includes 232 patients treated for up to 21 months.

This middle-aged woman attributes recent changes in her thinking and speech patterns to long-standing hypothyroidism. Do you concur?

The ELLDOPA trial results showed no significant difference with levodopa in combination with carbidopa between the patients who were treated early compared to those with delayed initiation.

The principal medical science director at Genentech spoke about how Floodlight works for physicians and patients and how it could improve care in MS.

A phase 3 trial of the therapy is ongoing after a number of positive signs from earlier assessments. Thus far, the tetrapeptide has shown potential to become the first treatment for PMM.

It is not clear why neurologists have attained the dubious honor of being tied for first place for burnout, but excessive clerical work, long hours, nights on call, and the pressure to see high numbers of complex patients probably contribute.

At the end of the 6-month, placebo-controlled treatment period, treatment with lemborexant at 5 mg or 10 mg resulted in statistically significant improvements compared to placebo in patient-reported sleep onset latency, subjective sleep efficiency, and subjective wake after sleep onset.

The phase 2 trial for the CGRP receptor agonist is planned for Q2 of 2019 after the intranasal treatment met its target therapeutic exposures in phase 1. Biohaven submitted an IND to the FDA in September 2018.

According to physician-reported data, the wearable PKG device provided data which resulted in an alteration in Parkinson management for 32% of patients.

The chief executive officer of C2N Diagnosis spoke about an investigational blood test used for screening of amyloid pathology in individuals being assessed for Alzheimer disease diagnosis.

The phase 1 trial assessed high doses of the therapy in 24 healthy volunteers, divvied up into 4 cohorts to receive doses, including 36 mg/kg, 60 mg/kg, 85 mg/kg, and 110 mg/kg. These data build upon the findings of the phase 2b CHANGE-MS trial.

The recall began in October 2018, was initiated due to a mislabeling on the pre-printed content on the infusion bag for lot ABD807. Thus far, there have been no reported adverse events related to this recall.

The Director of the Jefferson Headache Center spoke about migraine therapies that hold excitement and promise in the new year.

If the C2N brain amyloidosis test becomes FDA approved, this could be the first blood-based screening test to predict brain amyloid PET scan results in those with memory complaints or dementia.

Neurology News Network for the week of February 2, 2019.

The acute administration of adhesive dermally applied microarray zolmitriptan (Qytripta, Zosano Pharma) showed an almost uniform benefit across subgroups of patients with severe pain, delayed treatment, nausea, and who were awakening with headache.

The pediatric epileptologist and adjunct professor of pediatrics at the University of Calgary spoke about how broaching the topic of SUDEP has gone from undiscussed to a guideline-mandated practice in epilepsy.